Ramalingam Highlights Immunotherapy Advances in NSCLC – OncLive
OncLive |
Ramalingam Highlights Immunotherapy Advances in NSCLC
OncLive Recently reported updates from the KEYNOTE-189 and IMpower150 trials demonstrated the powerful impact of adding immunotherapy to treatment regimens for patients with non–small cell lung cancer (NSCLC). In the phase III KEYNOTE-189 study, the … |
